Baidu’s corporate venturing arm has re-invested in the immunotherapy developer to help commercialise its pipeline.

RootPath, a US-based cancer immunotherapy developer backed by internet company Baidu, has raked in $50m in a series B round.

Private equity firm CDH Investments and venture capital firm Sky9 Capital co-led the round, which was filled out by Matrix Partners China and Hony Capital. The round brings the company’s total funding to $68m.

Founded in 2017 out of biotech incubator Nest.Bio, RootPath develops personalised therapies designed to harness the immune system’s T-cells to target solid tumours through its synthetic…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn